StockData
Regeneron Pharmaceuticals, Inc. logo

Regeneron Pharmaceuticals, Inc.

REGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 16/3011% above fair value
$945.53−12.23 (-1.28%)

Close on Nov 18, 2026Market cap $97.81BP/E 20.9Yield –

Regeneron Pharmaceuticals Acquired In-Process Research and Development Expense by Quarter

Acquired In-Process Research and Development (IPR&D) Expense ($M) ($M)

Regeneron Pharmaceuticals Acquired In-Process Research and Development Expense: $21.5M in Q3 2026, down 74.1% from a year earlier.

Latest, Q3 2026
21.5
Period ended Sep 30, 2026
Change on a year earlier
-74.1%
83.1 in Q3 2025
History
23 quarters
Since Q1 2021
Sources
18
Documents cited below

Where the Q3 2026 figure comes from

Source: Form 10-Q (filed 2026-10-30) ↗

Reported in Form 10-Q / 10-K Consolidated Statements of Operations (XBRL).

quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedAcquired In-Process Research and Development (IPR&D) Expense ($M) ($M)Year on yearSource
Q3 2026Sep 30, 202621.5-74.1%Form 10-Q (filed 2026-10-30) ↗
Q2 2026Jun 30, 2026127+1,170.0%Form 10-Q (filed 2026-07-30) ↗
Q1 2026Mar 31, 2026102+728.5%Form 10-Q (filed 2026-04-29) ↗
Q4 2025Dec 31, 202518.7+35.5%Form 10-K (filed 2026-02-04) ↗
Q3 2025Sep 30, 202583.1+47.9%Form 10-Q (filed 2026-10-30) ↗
Q2 2025Jun 30, 202510-58.2%Form 10-Q (filed 2026-07-30) ↗
Q1 2025Mar 31, 202512.3+73.2%Form 10-Q (filed 2026-04-29) ↗
Q4 2024Dec 31, 202413.8-54.0%Form 10-K (filed 2026-02-04) ↗
Q3 2024Sep 30, 202456.2-43.8%Form 10-Q (filed 2025-10-28) ↗
Q2 2024Jun 30, 202423.9–Form 10-Q (filed 2025-08-01) ↗
Q1 2024Mar 31, 20247.10-87.3%Form 10-Q (filed 2025-04-29) ↗
Q4 2023Dec 31, 2023300.0%Form 10-K (filed 2026-02-04) ↗
Q3 2023Sep 30, 2023100–Form 10-Q (filed 2024-10-31) ↗
Q2 2023Jun 30, 20230-100.0%Form 10-Q (filed 2024-08-01) ↗
Q1 2023Mar 31, 202356.1+99.6%Form 10-Q (filed 2024-05-02) ↗
Q4 2022Dec 31, 202230-37.5%Form 10-K (filed 2025-02-05) ↗

Breakdown

What makes up acquired In-Process Research and Development Expense

Cite this data

StockData. (2026). Regeneron Pharmaceuticals Acquired In-Process Research and Development Expense ($M), quarterly Q1 2021–Q3 2026 [Data set]. Compiled from Regeneron Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/regn/kpis/iprd-exp

See every metric in the Regeneron Pharmaceuticals KPI table. Data updated Nov 4, 2026.

See a number that looks wrong?